Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156


Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis.

Holroyd CR, Parker L, Bennett S, Zarroug J, Underhill C, Davidson B, Armstrong R, Harvey NC, Dennison E, Cooper C, Edwards CJ.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):171-172. Epub 2018 Jan 15. No abstract available.


Functional implications of corticosteroid-binding globulin N-glycosylation.

Simard M, Underhill C, Hammond GL.

J Mol Endocrinol. 2018 Feb;60(2):71-84. doi: 10.1530/JME-17-0234. Epub 2017 Dec 22.


The impact of an inflammatory bowel disease nurse-led biologics service.

Taylor NS, Bettey M, Wright J, Underhill C, Kerr S, Perry K, Cummings JF.

Frontline Gastroenterol. 2016 Oct;7(4):283-288. doi: 10.1136/flgastro-2016-100696. Epub 2016 Jul 7.


Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.

Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, Dimopoulos MA, Miles Prince H.

Br J Haematol. 2017 May;177(3):441-448. doi: 10.1111/bjh.14562. Epub 2017 Feb 15.


Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.

Razanskaite V, Bettey M, Downey L, Wright J, Callaghan J, Rush M, Whiteoak S, Ker S, Perry K, Underhill C, Efrem E, Ahmed I, Cummings F.

J Crohns Colitis. 2017 Jun 1;11(6):690-696. doi: 10.1093/ecco-jcc/jjw216.


Feasibility and Safety of Irreversible Electroporation in Locally Advanced Pelvic and Retroperitoneal Tumors.

Underhill CE, Walsh NJ, Bateson BP, Mentzer C, Kruse EJ.

Am Surg. 2016 Sep;82(9):e263-5. No abstract available.


Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services.

Alexander M, Beattie-Manning R, Blum R, Byrne J, Hornby C, Kearny C, Love N, McGlashan J, McKiernan S, Milar JL, Murray D, Opat S, Parente P, Thomas J, Tweddle N, Underhill C, Whitfield K, Kirsa S, Rischin D.

Intern Med J. 2016 Aug;46(8):964-9. doi: 10.1111/imj.13157.


ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.

Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J.

BMC Cancer. 2016 May 31;16:339. doi: 10.1186/s12885-016-2389-8.


Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.

Harrison SJ, Mainwaring P, Price T, Millward MJ, Padrik P, Underhill CR, Cannell PK, Reich SD, Trikha M, Spencer A.

Clin Cancer Res. 2016 Sep 15;22(18):4559-66. doi: 10.1158/1078-0432.CCR-15-2616. Epub 2016 Apr 26.


Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD.

J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25.


Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.

Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavlakis N, Strickland A, Varma SC, Cooray P, Young R, Underhill C, Shannon JA, Ganju V, Gebski V.

Br J Cancer. 2016 Mar 1;114(5):505-9. doi: 10.1038/bjc.2015.440. Epub 2016 Feb 11.


Reorganization of mental health services: from institutional to community-based models of care.

Saraceno B, Gater R, Rahman A, Saeed K, Eaton J, Ivbijaro G, Kidd M, Dowrick C, Servili C, Funk MK, Underhill C.

East Mediterr Health J. 2015 Sep 28;21(7):477-85.


Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer.

Schofield PE, Stockler MR, Zannino D, Tebbutt NC, Price TJ, Simes RJ, Wong N, Pavlakis N, Ransom D, Moylan E, Underhill C, Wyld D, Burns I, Ward R, Wilcken N, Jefford M.

Support Care Cancer. 2016 Jan;24(1):401-8. doi: 10.1007/s00520-015-2792-8. Epub 2015 Jun 21.


Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

Brulé SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA.

Eur J Cancer. 2015 Jul;51(11):1405-14. doi: 10.1016/j.ejca.2015.03.015. Epub 2015 May 12.


Impact of corticosteroid-binding globulin deficiency on pregnancy and neonatal sex.

Lei JH, Yang X, Peng S, Li Y, Underhill C, Zhu C, Lin HY, Wang H, Hammond GL.

J Clin Endocrinol Metab. 2015 May;100(5):1819-27. doi: 10.1210/jc.2014-4254. Epub 2015 Feb 19.


Oncology service initiatives and research in regional Australia.

Murphy C, Sabesan S, Steer C, Yates P, Booms A, Jones V, Simpson A, Clarke K, Eek R, Ashley D, Goldstein D, Packer C, Tuthill F, Boyce A, Underhill C.

Aust J Rural Health. 2015 Feb;23(1):40-8. doi: 10.1111/ajr.12173.


Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study.

O'Carrigan B, Fournier M, Olver IN, Stockler MR, Whitford H, Toner GC, Thomson DB, Davis ID, Hanning F, Singhal N, Underhill C, Clingan P, McDonald A, Boland A, Grimison P; Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

Intern Med J. 2014 Aug;44(8):813-7. doi: 10.1111/imj.12500.


Pseudomonas aeruginosa elastase disrupts the cortisol-binding activity of corticosteroid-binding globulin.

Simard M, Hill LA, Underhill CM, Keller BO, Villanueva I, Hancock RE, Hammond GL.

Endocrinology. 2014 Aug;155(8):2900-8. doi: 10.1210/en.2014-1055. Epub 2014 May 21.


Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours.

Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, Gomez-Navarro J, Marshall MA, Huang B, Mather CB.

Br J Cancer. 2013 May 28;108(10):1998-2004. doi: 10.1038/bjc.2013.227. Epub 2013 May 7.


The relationship between use of CBT skills and depression treatment outcome: a theoretical and methodological review of the literature.

Hundt NE, Mignogna J, Underhill C, Cully JA.

Behav Ther. 2013 Mar;44(1):12-26. doi: 10.1016/j.beth.2012.10.001. Epub 2012 Oct 14. Review.


Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.

Olver IN, Grimison P, Chatfield M, Stockler MR, Toner GC, Gebski V, Harrup R, Underhill C, Kichenadasse G, Singhal N, Davis ID, Boland A, McDonald A, Thomson D; Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

Support Care Cancer. 2013 Jun;21(6):1561-8. doi: 10.1007/s00520-012-1696-0. Epub 2012 Dec 30.


Are visiting oncologists enough? A qualitative study of the needs of Australian rural and regional cancer patients, carers and health professionals.

Grimison P, Phillips F, Butow P, White K, Yip D, Sardelic F, Underhill C, Tse R, Simes R, Turley K, Raymond C, Goldstein D.

Asia Pac J Clin Oncol. 2013 Sep;9(3):226-38. doi: 10.1111/ajco.12014. Epub 2012 Sep 18.


Integrating mental health and development: a case study of the BasicNeeds Model in Nepal.

Raja S, Underhill C, Shrestha P, Sunder U, Mannarath S, Wood SK, Patel V.

PLoS Med. 2012;9(7):e1001261. doi: 10.1371/journal.pmed.1001261. Epub 2012 Jul 10. No abstract available.


Sitting with others: mental health self-help groups in northern Ghana.

Cohen A, Raja S, Underhill C, Yaro BP, Dokurugu AY, De Silva M, Patel V.

Int J Ment Health Syst. 2012 Mar 21;6(1):1. doi: 10.1186/1752-4458-6-1.


High frequency of SERPINA6 polymorphisms that reduce plasma corticosteroid-binding globulin activity in Chinese subjects.

Lin HY, Underhill C, Lei JH, Helander-Claesson A, Lee HY, Gardill BR, Muller YA, Wang H, Hammond GL.

J Clin Endocrinol Metab. 2012 Apr;97(4):E678-86. doi: 10.1210/jc.2011-3141. Epub 2012 Feb 15.


Phylogenetic comparisons implicate sex hormone-binding globulin in "masculinization" of the female spotted hyena (Crocuta crocuta).

Hammond GL, Miguel-Queralt S, Yalcinkaya TM, Underhill C, Place NJ, Glickman SE, Drea CM, Wagner AP, Siiteri PK.

Endocrinology. 2012 Mar;153(3):1435-43. doi: 10.1210/en.2011-1837. Epub 2012 Jan 17.


Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function.

Pawluski JL, Brain UM, Underhill CM, Hammond GL, Oberlander TF.

Psychoneuroendocrinology. 2012 Jul;37(7):1019-28. doi: 10.1016/j.psyneuen.2011.11.011. Epub 2011 Dec 15.


The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.

Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, Gebski VJ; Australasian Gastro-Intestinal Trials Group.

Br J Cancer. 2012 Jan 3;106(1):61-9. doi: 10.1038/bjc.2011.526. Epub 2011 Dec 1.


Partnerships for better mental health worldwide: WPA recommendations on best practices in working with service users and family carers.

Wallcraft J, Amering M, Freidin J, Davar B, Froggatt D, Jafri H, Javed A, Katontoka S, Raja S, Rataemane S, Steffen S, Tyano S, Underhill C, Wahlberg H, Warner R, Herrman H.

World Psychiatry. 2011 Oct;10(3):229-36.


Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review.

Butow PN, Phillips F, Schweder J, White K, Underhill C, Goldstein D; Clinical Oncological Society of Australia.

Support Care Cancer. 2012 Jan;20(1):1-22. doi: 10.1007/s00520-011-1270-1. Epub 2011 Sep 29. Review.


An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009.

Lingaratnam S, Slavin MA, Mileshkin L, Solomon B, Burbury K, Seymour JF, Sharma R, Koczwara B, Kirsa SW, Davis ID, Prince M, Szer J, Underhill C, Morrissey O, Thursky KA.

Intern Med J. 2011 Jan;41(1b):110-20. doi: 10.1111/j.1445-5994.2010.02342.x.


Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee.

Lingaratnam S, Slavin MA, Koczwara B, Seymour JF, Szer J, Underhill C, Prince M, Mileshkin L, O'Reilly M, Kirsa SW, Bennett CA, Davis ID, Morrissey O, Thursky KA; Australian Consensus Guidelines 2011 Steering Committee.

Intern Med J. 2011 Jan;41(1b):75-81. doi: 10.1111/j.1445-5994.2010.02338.x.


Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.

Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M.

Clin Cancer Res. 2011 Mar 1;17(5):1147-59. doi: 10.1158/1078-0432.CCR-10-1869. Epub 2011 Jan 10.


(Arene)Cl₂Ru(II) complexes with N-coordinated estrogen and androgen isonicotinates: interaction with sex hormone binding globulin and anticancer activity.

Schobert R, Seibt S, Effenberger-Neidnicht K, Underhill C, Biersack B, Hammond GL.

Steroids. 2011 Mar;76(4):393-9. doi: 10.1016/j.steroids.2010.12.009. Epub 2010 Dec 22.


A review of PARP inhibitors: from bench to bedside.

Underhill C, Toulmonde M, Bonnefoi H.

Ann Oncol. 2011 Feb;22(2):268-79. doi: 10.1093/annonc/mdq322. Epub 2010 Jul 19. Review.


Novel corticosteroid-binding globulin variant that lacks steroid binding activity.

Perogamvros I, Underhill C, Henley DE, Hadfield KD, Newman WG, Ray DW, Lightman SL, Hammond GL, Trainer PJ.

J Clin Endocrinol Metab. 2010 Oct;95(10):E142-50. doi: 10.1210/jc.2010-0746. Epub 2010 Jul 7.


Mentoring in the management of hematological malignancies.

Underhill C, Koschel A, Szer J, Steer C, Clarke K, Grigg A, Juneja S, Stella D, Francis H, Josselyn K.

Asia Pac J Clin Oncol. 2010 Mar;6(1):28-34. doi: 10.1111/j.1743-7563.2010.01274.x.


Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.

Gibbs P, Clingan PR, Ganju V, Strickland AH, Wong SS, Tebbutt NC, Underhill CR, Fox RM, Clavant SP, Leung J, Pho M, Brown TJ.

Cancer Chemother Pharmacol. 2011 Jan;67(1):153-63. doi: 10.1007/s00280-010-1303-3. Epub 2010 Mar 24.


Reaching further with online education? The development of an effective online program in palliative oncology.

Koczwara B, Francis K, Marine F, Goldstein D, Underhill C, Olver I.

J Cancer Educ. 2010 Sep;25(3):317-23. doi: 10.1007/s13187-009-0037-6.


Mapping oncology services in regional and rural Australia.

Underhill C, Bartel R, Goldstein D, Snodgrass H, Begbie S, Yates P, White K, Jong K, Grogan P.

Aust J Rural Health. 2009 Dec;17(6):321-9. doi: 10.1111/j.1440-1584.2009.01106.x.


Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.

Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, de Souza P, Boyce A, Parnis F, Lim V, Harvie R, Marx G.

Ann Oncol. 2010 Jun;21(6):1302-7. doi: 10.1093/annonc/mdp524. Epub 2009 Nov 16.


Effects of aggressive encounters on plasma corticosteroid-binding globulin and its ligands in white-crowned sparrows.

Charlier TD, Underhill C, Hammond GL, Soma KK.

Horm Behav. 2009 Sep;56(3):339-47. doi: 10.1016/j.yhbeh.2009.06.012. Epub 2009 Jul 8.


Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?

Bonnefoi H, Underhill C, Iggo R, Cameron D.

Eur J Cancer. 2009 Jul;45(10):1733-43. doi: 10.1016/j.ejca.2009.04.036. Epub 2009 May 26. Review.


An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.

Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B, Toner GC.

Am J Clin Oncol. 2009 Aug;32(4):338-41. doi: 10.1097/COC.0b013e31818b946b.


Residues in the human corticosteroid-binding globulin reactive center loop that influence steroid binding before and after elastase cleavage.

Lin HY, Underhill C, Gardill BR, Muller YA, Hammond GL.

J Biol Chem. 2009 Jan 9;284(2):884-96. doi: 10.1074/jbc.M807376200. Epub 2008 Nov 14.


Success indicators for integrating mental health interventions with community-based rehabilitation projects.

Raja S, Boyce WF, Ramani S, Underhill C.

Int J Rehabil Res. 2008 Dec;31(4):284-92. doi: 10.1097/MRR.0b013e3283013b0b.


A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.

Pasricha SR, Grigg A, Catalano J, Leahy M, Underhill C, Arthur C, D'Rozario J, Lowenthal R, Reed K, Spencer A.

Cancer. 2008 Dec 1;113(11):3192-8. doi: 10.1002/cncr.23915.


Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.

Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, Taylor K, Arthur C, Schwarer A, Morton J, Cooney J, Leahy MF, Rowlings P, Catalano J, Hertzberg M, Filshie R, Mills AK, Fay K, Durrant S, Januszewicz H, Joske D, Underhill C, Dunkley S, Lynch K, Grigg A; Australasian Leukaemia and Lymphoma Group.

Blood. 2008 Nov 15;112(10):3965-73. doi: 10.1182/blood-2008-06-161737. Epub 2008 Sep 3.


In silico identification of anthropogenic chemicals as ligands of zebrafish sex hormone binding globulin.

Thorsteinson N, Ban F, Santos-Filho O, Tabaei SM, Miguel-Queralt S, Underhill C, Cherkasov A, Hammond GL.

Toxicol Appl Pharmacol. 2009 Jan 1;234(1):47-57. doi: 10.1016/j.taap.2008.07.014. Epub 2008 Jul 25.


Characterization and measurement of the plasma alpha- and beta-sex hormone-binding globulin paralogs in salmon.

Miguel-Queralt S, Underhill C, Devlin RH, Hammond GL.

Endocrinology. 2009 Jan;150(1):366-75. doi: 10.1210/en.2008-0964. Epub 2008 Aug 14.


Supplemental Content

Loading ...
Support Center